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Background:  Electronic  cigarettes  (ECs)  and nicotine  replacement  therapy  (NRT)  are  non-combustible
nicotine  delivery  devices  being  widely  used  as  a partial  or a complete  long-term  substitute  for  smoking.
Little  is  known  about  the  characteristics  of  long-term  users,  their  smoking  behaviour,  attachment  to
smoking,  experience  of  nicotine  withdrawal  symptoms,  or their  views  on these  devices.  This study  aimed
to provide  preliminary  evidence  on this  and  compare  users  of the  different  products.
Methods: UK  participants  were  recruited  from  four  naturally  occurring  groups  of  long-term  (≥6  months)
users  of  either  EC or NRT  who  had  stopped  or continued  to smoke  (N =  36  per group, total  N  =  144).  Par-
ticipants  completed  a  questionnaire  assessing  socio-demographic  and  smoking  characteristics,  nicotine
withdrawal  symptoms,  smoker  identity  and  attitudes  towards  the  products  they  were  using.
Results:  Adjusting  for relevant  confounders,  EC  use  was  associated  with  a  stronger  smoker  identity
(Wald  X2(1) =  3.9,  p =  0.048)  and  greater  product  endorsement  (Wald  X2(1)  =  4.6, p = 0.024)  than  NRT  use,
irrespective  of  smoking  status.  Among  ex-smokers,  EC users  reported  less  severe  mood  and  physical
symptoms  (Wald  X2(1)  = 6.1,  p =  0.014)  and  cravings  (Wald  X2(1)  = 8.5, p = 0.003),  higher  perceived  help-
fulness  of the  product  (Wald  X2(1)  =  4.8,  p = 0.028)  and lower  intentions  to stop  using  the product  (Wald
2X (1) =  17.6,  p <  0.001)  than  NRT  users.
Conclusions:  Compared  with  people  who  use NRT  for at least  6  months,  those  who  use  EC over  that
time  period  appear  to have  a stronger  smoker  identity  and  like their  products  more.  Among  long-term
users  who  have  stopped  smoking,  ECs are  perceived  as more  helpful  than  NRT, appear  more  effective  in
controlling  withdrawal  symptoms  and  continued  use  may  be  more  likely.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
Despite the huge burden of tobacco smoking on health (Doll
t al., 2004; WHO, 2012), smokers struggle to quit successfully and
lobal smoking prevalence remains stubbornly high (Eriksen et al.,
012). Stopping smoking is largely difﬁcult because of the highly
ddictive properties of nicotine (Watkins et al., 2000). Nicotine
ithdrawal produces both physical symptoms (e.g., tremors)
nd mood symptoms (e.g., elevated anxiety), and causes the
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niversity College London, 1–19 Torrington Place, London, WC1E 6BT, UK.
el.: +44 207679 1805; fax: +44 207813 2848.
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376-8716/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
majority of smokers making an unassisted quit attempt to return
to smoking within two weeks (Hughes et al., 2004). Thus, nicotine
withdrawal may  be a useful target to support long-term transitions
to smoking reduction or complete smoking cessation. This is the
rationale for the provision of medicinal nicotine in the form of
nicotine replacement therapy (NRT), which has been shown in
randomised trials to increase quit rates by 50 to 70% (Stead et al.,
2012). However, beyond smoking cessation, for smokers who are
unwilling or unable to quit, NRT use for harm reduction may be
a valuable strategy in reducing the burden of tobacco use, and in
the UK, guidelines recommend this approach for these smokers
(NICE, 2013). As the combustion of cigarettes is recognised as the
primary cause of cigarette toxicity, harm reduction in this context
is deﬁned as the use of non-combustible forms of nicotine delivery
to partially or fully replace combustible forms such as cigarettes
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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above 10 ppm indicated current smoking. Due to the collection of biological samples
(not reported here), participants were excluded if they were younger than 18 years
old, had a history of heart or lung disease, were pregnant, or had bleeding gums,V.A. Nelson et al. / Drug and Alco
n the long run (Le Houezec et al., 2011). Research suggests
hat a substantial minority of smokers use NRT for long-term
arm reduction, e.g. for temporary abstinence or to cut-down on
igarettes, and that this may  be increasing (Beard et al., 2011;
ammond et al., 2008; Levy et al., 2007; Silla et al., 2014).
In addition to traditional NRT, electronic cigarette (EC) is another
on-combustible nicotine delivery device which has gained a wide
opularity in recent years (Brown et al., 2014b; King et al., 2013;
ardavas et al., 2014) and potentially may  be particularly suited
or harm reduction, given high levels of dual use in the popula-
ion (McMillen et al., 2014) and continued long-term single and
ual use in clinical trials (Shahab and Goniewicz, 2014). EC usu-
lly consists of a battery, heating element, and a tank or a cartridge
ontaining a nicotine solution (‘e-liquid’). The battery is typically
ctivated either manually or by inhalation through the device, and
roduces an aerosol that can be inhaled by the user. Although some
oxic chemicals have been detected in EC aerosol (Goniewicz et al.,
013; Schober et al., 2014; Vardavas et al., 2012), it does not contain
ar, or most of the other chemical compounds detected in cigarette
moke, as the process does not involve combustion, resulting in
evels of toxicants at least an order of magnitude lower than that in
igarette smoke (Goniewicz et al., 2014; Kosmider et al., 2014). Thus
C can arguably be considered a much safer alternative to smok-
ng cigarettes (Hajek et al., 2014). ECs have also been demonstrated
o increase cessation rates in clinical trials (McRobbie et al., 2014)
nd some population studies (Biener and Hargraves, 2015; Brown
t al., 2014a), but not all observational studies have detected an
ffect (Grana et al., 2014), and more research is needed to conﬁrm
C effectiveness, using an appropriate methodology to distinguish
etween the impact of EC use on cessation when used as part of
 quit attempt vs. when it is used for any general purpose (Hajek
t al., 2014).
Although some concerns remain in the population regarding
he safety of prolonged use of non-combustible nicotine delivery
evices (Black et al., 2012; Dockrell et al., 2013), the evidence
ndicates that long-term NRT use is safe in terms of levels of
icotine delivered (Shahab et al., 2014) and associated toxicity
Benowitz and Gourlay, 1997; Hubbard et al., 2005) and grow-
ng data on EC would suggest the same (Hajek et al., 2014). This,
ombined with the known toxicity of combustible nicotine use,
urther supports the idea of harm reduction, shifting smokers
owards non-combustible nicotine delivery devices and away from
moked tobacco. However, relatively little is known about the
rocesses which underpin a smoker’s transition to sole use of non-
ombustible nicotine delivery devices and whether long-term use
f such products aids cessation or maintains smoking in the long
un.
One universal mechanism worth investigating in the context of
nderstanding this transition is “smoker identity”, the self-concept
hat being a smoker is an essential constituent of one’s identity
Shadel and Mermelstein, 1996; Shadel et al., 1996). It has been
osited that identity inﬂuences behaviour by creating strong wants
r needs, such as wanting to be a non-smoker, which compete with
xternal impulses, such as the desire to smoke, and may  there-
ore reinforce or undermine shifts in behaviour (West and Brown,
013). Studies have observed a weakening in smoker identity dur-
ng cessation as smokers distanced themselves from an unwanted
moker identity (Johnson et al., 2003; Vangeli and West, 2012), and
iking being a smoker has been identiﬁed as an important barrier to
moking cessation (Tombor et al., 2013; van den Putte et al., 2009).
Another important factor in the transition from smoker to non-
moker is the physiological impact of cessation. The role of mood
nd physical symptoms in relapse is well-documented (West et al.,
989), and even after long periods of abstinence the presence
f withdrawal symptoms has been shown to predict return to
moking (Piasecki et al., 2003). In line with existing theory (Westependence 153 (2015) 300–305 301
and Brown, 2013), it is therefore important that such symptoms
are minimised to ensure the motivation not to smoke remains
stronger than the motivation to smoke. For this reason, effec-
tive harm reduction should treat negative mood and physical
symptoms.
Lastly, attitudes towards the product, e.g., in terms of sat-
isfaction or intention to stop its use, are likely to inform its
suitability for long-term harm reduction purposes, on the one hand,
and transition towards complete cessation of all nicotine prod-
ucts, on the other. Ideally, all factors that are likely to inﬂuence
the product–contingent transition from smoking to non-smoking
would be assessed prospectively. However, given the length of
time needed to evaluate the use of non-combustible nicotine prod-
ucts for harm reduction appropriately, this study used a pragmatic
approach, purposively selecting participants who had been using
products for at least six months.
In order to evaluate the transitions from smoking to non-
smoking, both smokers and ex-smokers using non-combustible
nicotine delivery devices were selected. In addition, comparisons
were made between EC and NRT users to determine the relative
associations with the modality of nicotine delivery. Given the rel-
ative lack of data on EC, NRT was deemed a useful comparator as
it has well-established effectiveness. Speciﬁcally, the present study
assesses the associations between smoking status and product type
among long-term users of EC or NRT with (1) smoker identity, (2)
withdrawal symptoms, and (3) attitudes towards non-combustible
nicotine delivery devices.
2. Methods
2.1. Study design and procedure
This cross-sectional study forms part of a larger, international study assess-
ing the impact of long-term use of non-combustible nicotine delivery devices on
health (currently being prepared for publication). The present study, which focuses
on  psychological measures collected only in the UK sub-sample, also involved the
collection of biological samples (not reported here) as well as administration of
a  questionnaire at a single laboratory appointment, lasting approximately 30 min.
Smokers and ex-smokers using either EC or NRT on a long-term basis of at least six
months were purposively recruited, resulting in four groups of participants: cur-
rent and ex-smokers using NRT and current and ex-smokers using EC. Participants
were screened into these four naturally occurring groups to allow for comparisons
between EC and NRT use, and between smoking status. Participants were reim-
bursed for time and travel. The study received ethical approval from the University
College London (UCL) Ethics Committee (Project ID 0483/002).
2.2. Participants
Participants were told that this study was about the effects of long-term use of
non-combustible nicotine delivery devices and recruited in the greater London, UK
area during January–July, 2014 using various recruiting methods to access a diverse
sample. These included adverts in newspapers, Facebook, online electronic cigarette
forums, posters in independent pharmacies, emails to students and staff at UCL, the
use of an online smokers panel as well as marketing companies.
Participants were screened for eligibility via phone or online questionnaires.
Inclusion criteria were based on long-term product use in order to control for a
noted learning curve in effective EC use (e.g., Bullen et al., 2013). Ex-smokers had to
have quit any tobacco products (including waterpipe, cigars, smokeless products) for
six months, use their non-combustible nicotine delivery device weekly for the past
six months, and not use other non-combustible nicotine delivery devices regularly
(i.e.,  ex-smoker NRT users could not use EC regularly and vice versa). Smokers had
to  smoke an average of one cigarette per day and meet the same non-combustible
nicotine delivery device use criteria as ex-smokers. Current smoking status was
veriﬁed using a breathalyser to assess expired air carbon-monoxide (CO); readingsillness, or infection within 24 h of their scheduled appointment.
Thirty-six participants were recruited into each of the four study groups which
provided sufﬁcient power to detect a medium-sized effect on outcome measures
(Cohen’s d = 0.40, see Kraemer and Kupfer, 2006). Data for all participants (N = 144)
are  provided in Table 1.
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Table  1
Socio-demographic, smoking and product use characteristics by study group.
Total (N = 144) EC users NRT users
Ex-smoker (N = 36) Smoker (N = 36) Ex-smoker (N = 36) Smoker (N = 36)
Socio-demographics
Mean age (SD) 38.6 (11.0) 38.5 (11.1) 39.3 (13.1) 40.3 (11.1) 36.4 (8.5)
%  Male (N) 61.8 (89) 80.6 (29)a 69.4 (25)a 58.3 (21)a,b 38.9 (14)b
%  White (N) 70.1 (101) 83.3 (30) 75.0 (27) 63.9 (23) 58.3 (21)
%  Married/cohabiting (N) 42.4 (61) 33.3 (12)a,b 27.9 (10)a 61.1 (22)b 47.2 (17)a,b
%  University degree (N) 56.2 (81) 50.0 (18) 50.0 (18) 58.3 (21) 66.7 (24)
Smoking characteristics
Mean length of smoking, years (SD) 18.9 (11.1) 19.0 (11.5) 21.5 (12.2) 17.1 (10.5) 18.0 (10.1)
Mean cigarettes per daya (SD) 13.5 (8.6) 16.5 (8.0)a 11.9 (9.6)a,b 14.7 (10.3)a,b 10.8 (4.6)b
Mean  length stopped smoking, months (SD) 18.1 (17.5) 19.7 (15.7) – 16.5 (19.2) -
Mean  FTCD (SD) 3.0 (2.1) – 3.1 (1.9) – 2.8 (2.2)
%  Currently trying to cut down 84.5 (60) – 80.0 (28) – 88.9 (32)
Mean  MTTS (SD) 4.5 (1.8) – 3.9 (2.1)a – 5.1 (1.4)b
Mean  number of quit attempts in the past year (SD) 1.3 (1.7) – 0.8 (1.0)a – 1.7 (2.0)b
Mean  CO level in ppm (SD) 5.5 (5.4) 2.8 (1.1)a 8.3 (5.5)b 3.3 (3.2)a 7.7 (7.2)b
Productb use characteristics
Mean length of product use, months (SD) 16.6 (17.0) 20.1 (15.4) 14.5 (9.1) 15.8 (24.8) 16.0 (15.0)
Mean product use, nicotine mg/day (SD) 21.0 (25.9) 32.6 (34.1)a 20.5 (33.0)a,b 17.0 (15.6)a,b 13.1 (7.8)b
%  Use product within 1 h of waking (N) 56.9 (82) 80.6 (29)a 44.4 (16)b 63.9 (23)a,b 38.9 (14)b
FTCD – Fagerstrom test of cigarette dependence (Fagerstrom 2012); MTSS – Motivation to stop scale (Kotz et al., 2013); NRT – nicotine replacement therapy; EC – electronic
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digarette; CO – carbon-monoxide. Different letters between groups indicate signiﬁc
a Current consumption for smokers, past consumption for ex-smokers.
b Product’ refers to NRT or EC.
.3. Measures
.3.1. Outcome measures. Based on work underlining the validity of simple mea-
ures of smoker identity (e.g., Tombor et al., 2013), the present study used an
stablished item to determine smoker identity strength (Shadel and Mermelstein,
996): participants were asked to rank their agreement with the statement,
Smoking is a part of me’  on a Likert scale of 1 (‘not at all’) to 5 (‘completely
gree’).
Withdrawal symptoms were assessed with the validated Mood and Physical
ymptoms Scale (MPSS, West and Hajek, 2004; West et al., 2006) which assesses
ravings (two items; cigarette craving strength and frequency; range 0–5 per item,
rom ‘no urges’/‘not at all’ to ‘extremely strong’/‘all the time’) and other general
ood and physical symptoms related to withdrawal (seven items; being irritable,
estless, depressed, hungry, anxious, subjected to poor sleep, poor concentration;
ange 1–5 per item, from ‘not at all’ to ‘extremely’).
Attitudes towards NRT or EC were assessed with three measures. Intention to
top product use was measured using a modiﬁed version of the motivation to stop
cale (Kotz et al., 2013), replacing the term ‘cigarette’ with ‘e-cigarette’ or ‘NRT’,
nd  with higher values indicating greater motivation to stop use (seven response
ptions; ranging from ‘I don’t want to stop’ to ‘I really want to stop and intend to
n  the next months’). Using 5-point Likert scales, participants were further asked
hether they found the product helpful in enabling them to refrain from smok-
ng, with response options ranging from ‘not at all helpful’ to ‘extremely helpful’
nd whether they would recommend the product to a friend who  wanted to stop
moking, with response options ranging from ‘deﬁnitely not’ to ‘deﬁnitely’.
.3.2. Covariates. Standard socio-demographic and smoking characteristics,
ncluding age, sex, ethnicity, education, length of current/past smoking, current
r  past cigarettes smoked per day, cigarette dependence, motivation to stop,
umber of quit attempts were also measured. In addition, a number of product
se characteristics were assessed such as length and frequency of product use
see Table 1). Participants were asked to indicate the length of use, latency to use
he product in the morning as an indicator of dependence and consumption. The
atter was  assessed by asking NRT users to indicate the strength and the type of
he  product used and quantity used per day, week, or month. EC users were also
sked about the type of the product they used; those using ﬁrst generation EC
disposable/re-chargeable) and those using second or third generation EC (reﬁllable
r  advanced personal vaporisers) were asked to indicate, respectively, either the
icotine content of the disposable/cartridge or the concentration of the e-liquid
sed as well as the quantity used per day, week, or month. Please refer to the
upplementary information for the full questionnaire.
.4. AnalysisAnalyses were conducted with SPSS Version 21.0. Simple associations between
tudy groups and continuous demographic variables, smoking characteristics, and
roduct use characteristics were assessed with one-way ANOVAs or indepen-
ent t-tests, and categorical variables were assessed with chi-square analysis,fferences at p < 0.05.
controlling for family-wise error rate using the false discovery rate (Benjamini
and Hochberg, 1995) and for multiple comparisons using the Sidak correc-
tion in post hoc analysis. Generalised linear models were used to assess
main or interaction effects of product use (EC versus NRT) and smoker sta-
tus (ex- versus current smoker) on smoker identity, withdrawal symptoms,
and  attitudes towards the product, controlling for relevant covariates (as listed
in  Fig. 1).
3. Results
Compared with the UK general population (Ofﬁce for National
Statistics, 2012), the present sample was  younger, and more likely
to be white, male, educated, and cohabiting or married (Table 1).
Cigarette consumption reﬂected national data (e.g., Fidler et al.,
2011) and participants had smoked for nearly 20 years on average
and had used either NRT or e-cigarettes for about one–and-a-half
years. Ex-smokers had also stopped for about one-and-a-half years
and had signiﬁcantly lower levels of CO than current smokers
(Table 1). The four groups were balanced among the majority of
socio-demographic and smoking characteristics measured. How-
ever, there were signiﬁcantly more male smokers using EC than
smokers using NRT, and more cohabiting smokers using NRT than
EC (Table 1). As would be expected, current cigarette consump-
tion was lower among dual users than past cigarette consumption
reported by ex-smokers and four out of ﬁve smokers reported try-
ing to cut down cigarette consumption. Amongst smokers, NRT
users reported having made more recent quit attempts and being
more motivated to quit than EC users (Table 1). While there were no
differences in terms of the length of product use, EC users reported
greater daily nicotine consumption than NRT users, and ex-smokers
generally had a shorter latency to product use in the morning than
smokers (Table 1).
3.1. Associations with smoker identity
In order to control for possible confounding inﬂuences, all socio-
demographic, smoking, and product use characteristics with data
available for all groups were included as covariates in further anal-
ysis. Generally, a stronger smoker identity was associated with
greater current or past cigarette consumption (Wald X2(1) = 4.6,
V.A. Nelson et al. / Drug and Alcohol Dependence 153 (2015) 300–305 303
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Fig. 1. Association of smoking status and product type with smoker identity (A), withdrawal symptoms (B, C) and attitudes towards the products (D–F); Estimated marginal
means  are adjusted for age, gender, ethnicity, marital status, education, length of smoking, number of cigarettes smoked per day, length of product use, product consump-
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sion  level and latency to product use; error bars are SEM; grey circles denote nico
sers.
 = 0.031) and with being female (Wald X2(1) = 7.6, p = 0.006). How-
ver, there was no interaction of smoking status by the product
ype (Wald X2(1) = 1.1, ns). As would be expected, there was  a main
ffect of smoking status on smoker identity (Wald X2(1) = 29.5,
 < 0.001): current smokers expressed a stronger smoker identity
han ex-smokers. There was also a main effect of the product type
Wald X2(1) = 3.9, p = 0.048): smoker identity was more pronounced
mong EC users than NRT users, irrespective of smoking status and
ther covariates (see Fig. 1A).
.2. Associations with withdrawal symptoms
In terms of withdrawal symptoms, higher current/past cigarette
onsumption (Wald X2(1) = 8.7, p = 0.003) and being female (Wald
2(1) = 4.5, p = 0.034) were associated with more pronounced mood
nd physical withdrawal symptoms in this sample. In addition,
here was a signiﬁcant interaction of product type and smoking
tatus (Wald X2(1) = 6.1, p = 0.014). As shown in Fig. 1B, while there
as no product-dependent difference among smokers, ex-smokers
ho use NRT reported higher mood and physical withdrawal symp-
oms than ex-smokers using EC. These ﬁndings are largely mirrored
hen looking at reported cravings. As before, there was  a signiﬁ-
ant product type by smoking status interaction, such that NRT use
as associated with greater cravings only among ex- but not cur-
ent smokers (Wald X2(1) = 8.5, p = 0.003, Fig. 1C). In addition, the
esults indicated that lower product use (as measured by average
aily nicotine intake derived from products) was  associated with
tronger cravings (Wald X2(1) = 6.8, p = 0.009)..3. Associations with attitudes towards products
Non-white participants in this sample were more likely to con-
ider stopping the use of non-combustible nicotine delivery deviceseplacement therapy (NRT) users; black squares indicate electronic cigarette (EC)
(Wald X2(1) = 6.2, p = 0.013) as were those participants who had
used products for longer (Wald X2(1) = 9.4, p = 0.002). In addition,
there was also a clear product type by smoking status interaction
on intention (Wald X2(1) = 17.6, p < 0.001): whilst NRT users were
generally more likely to intend to stop using their product than EC
users, this difference was signiﬁcantly stronger among ex-smokers
than smokers (see Fig. 1D). Similarly, product type interacted with
smoking status on the perceived helpfulness of the product (Wald
X2(1) = 4.8, p = 0.028). ECs were generally rated as more helpful for
keeping off cigarettes than NRT but again, this difference was signif-
icantly stronger among ex-smokers than smokers (Fig. 1E). Lastly,
there were main effects of product type (Wald X2(1) = 4.6, p = 0.032)
and smoking status (Wald X2(1) = 5.1, p = 0.024) for recommending
the product to others but no interaction (Wald X2(1) = 0.4, ns). EC
users or ex-smokers were signiﬁcantly more likely to recommend
the product as an aid to smoking cessation than NRT users or current
smokers (Fig. 1F).
4. Discussion
The long-term use of e-cigarettes compared with licensed NRT
by ex- and current smokers is associated with a stronger smoker
identity and product endorsement. Among ex-smokers only, EC as
compared with NRT use is associated with lower withdrawal symp-
toms, greater perceived helpfulness of the product for stopping
smoking and weaker intention to stop product use.
As in this study, previous work suggests that smoker iden-
tity may  play a role in product use and smoking status (Tombor
et al., 2013; Vangeli and West, 2012). Given e-cigarette users had
a stronger smoker identity than NRT users irrespective of whether
they smoked or had stopped smoking, the present results support
the common-sense assumption that ECs have a particular appeal
for those who identify more strongly with smoking. This may be
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ue to a greater similarity between smoking cigarettes and vap-
ng and could also reﬂect the possibility that EC may  be viewed as
 consumer product for recreational use whereas NRT is seen as a
edicinal product for treatment purposes. Alternatively, it could be
hat EC and NRT users do not differ initially but that EC use sustains
moker identity or that NRT use undermines this identity over time.
his cross-sectional study cannot distinguish these possibilities.
Nicotine craving and mood and physical withdrawal symptoms
ere virtually non-existent among ex-smokers using EC and signif-
cantly lower than among ex-smokers using NRT. While previous
esearch indicates both NRT (Moore et al., 2009; Stead et al., 2012)
nd EC (Hajek et al., 2014; McRobbie et al., 2014) can be useful for
essation and harm reduction purposes, our study suggests that
n experienced users EC may  be especially effective at reducing
icotine withdrawal. Given that this sample comprises long-term
sers, this effect is unlikely to be the result of incorrect product
se. Notwithstanding the adjustment for smoking characteristics
n the analysis, this result may  also again reﬂect self-selection (i.e.,
x-smokers who use EC may  have had lower dependence to start
ff with and thus would experience less withdrawal).
ECs were rated as more helpful for stopping smoking than NRT
y ex-smokers using these products. EC users, in particular, ex-
mokers, were consequently less likely than NRT users to intend
o stop using the product. In addition, motivation to stop smoking
nd the number of past year quit attempts were greater among
mokers who concurrently used NRT than EC. Taken together, these
ndings are consistent with a gradual transition towards a non-
moker identity among long-term NRT users who smoke (Silla et al.,
014) and reﬂect a possible identity shift among ex-smokers which
ay involve the want to be free of any nicotine products (Vangeli
nd West, 2012).
On the one hand, ﬁndings are encouraging insofar as they sug-
est that EC could be a powerful harm reduction tool, at least as
ffective as the established NRT, and that they may  be particu-
arly helpful in engaging those smokers who are not motivated
o quit and/or strongly identiﬁed as smokers. Indeed, it has been
eported that a minority of long-term ex-smokers maintain a strong
moker identity (Vangeli et al., 2010). For these ex-smokers, in par-
icular, EC may  enable complete substitution of combustible with
on-combustible nicotine delivery devices. On the other hand, it
s possible that if a stronger smoking identity is maintained by EC
se, this may  undermine long-term outcomes as establishing a ﬁrm
on-smoker identity may  be important to resist relapse to smoking
Tombor et al., 2015). However, such speculations need to be tested
n experimental design.
This study has several limitations which restrict the conclu-
ions that can be drawn from the present study. First, although
iverse recruitment methods were used, the sample was pur-
osively selected and thus ﬁndings may  not generalise to the
eneral population. However, relevant confounders were con-
rolled for to reduce selection bias, and the distribution of
articipant characteristics was roughly similar to those found in
arger, broadly representative studies of non-combustible nicotine
elivery devices (Brown et al., 2014b; Silla et al., 2014). Second,
ue to the cross-sectional design, it is not possible to determine the
irection of the association between product choice and outcome
ariables as these may  be due to self-selection. While a prospective
esign would be preferable, given the relative novelty of EC and the
ssociated lack of data on this topic, we chose this pragmatic design
o pin-point important associations with long-term use now which
an be investigated further in longitudinal studies. Third, although
moking status was veriﬁed and validated self-report measures
ere used, these may  not be able to capture fully complex concepts
uch as smoker identity.
In light of these ﬁndings, future research should continue to
xplore and clarify the association of smoker identity, withdrawalependence 153 (2015) 300–305
symptoms and attitudes towards the products with long-term use
of NRT and EC among smokers and ex-smokers. In particular, it
would be important to establish whether smoker identity and
intentions to stop nicotine use inﬂuence product choice or whether
product use impacts the strength of smoker identity and the deci-
sion to stop nicotine use completely. Notwithstanding the potential
of self-selection bias given the cross-sectional nature of data, the
observed interactions of product use with smoking status are con-
sistent with EC being a particularly suitable harm reduction tool
to switch smokers from combustible tobacco to permanent non-
combustible nicotine use whereas NRT may  be more suitable as
harm reduction tool in the short-to-intermediate term.
In conclusion, long-term EC use is associated with a stronger
smoker identity and positive attitudes towards the product than
the long-term NRT use. ECs are generally perceived as more helpful
than NRT for stopping smoking by ex-smokers and may  be more
effective at reducing withdrawal symptoms. Based on self-reported
intention to stop product use, NRT compared with EC may  also be
more likely to result in complete cessation of nicotine among long-
term users who have stopped smoking.
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